Last reviewed · How we verify
SPC3001
At a glance
| Generic name | SPC3001 |
|---|---|
| Also known as | Candesartan 8mg |
| Sponsor | Shin Poong Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPC3001 CI brief — competitive landscape report
- SPC3001 updates RSS · CI watch RSS
- Shin Poong Pharmaceutical Co. Ltd. portfolio CI